Kymera Therapeutics (KYMR) Projected to Post Quarterly Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.76) per share and revenue of $14.81 million for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Kymera Therapeutics Stock Down 4.1 %

Kymera Therapeutics stock opened at $35.31 on Tuesday. The company has a market capitalization of $2.29 billion, a P/E ratio of -15.09 and a beta of 2.18. The stock’s 50 day moving average is $39.61 and its 200 day moving average is $44.02. Kymera Therapeutics has a twelve month low of $29.24 and a twelve month high of $53.27.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, insider Ellen Chiniara sold 3,129 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the transaction, the insider now directly owns 54,826 shares in the company, valued at approximately $2,288,985.50. This trade represents a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 15.82% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

KYMR has been the topic of several recent research reports. Truist Financial restated a “buy” rating and issued a $53.00 price target (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Stephens reaffirmed an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. BMO Capital Markets assumed coverage on Kymera Therapeutics in a research report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price objective on the stock. Morgan Stanley upped their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 6th. Finally, UBS Group lowered their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $55.64.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.